Sanofi cancer drug expands

Posted 27 January 2022 AM

Sanofi was among a few companies that slipped through new indications for their therapies before the end of 2021, again pushing forward its PD-1 inhibitor Libtayo.

A TGA update detailing new or extended uses registered in December reveals it took only 43 working days to provisionally approve Libtayo for treatment of adults with a type of skin cancer called metastatic basal cell carcinoma (BCC) while it granted full registration for patients with locally advanced disease.

To see the whole article, please login